Article

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutation

2024-01-31

Abstract excerpt

<h4>Purpose: </h4> Children with unresectable cervico-medullary low-grade glial tumors (CMTs) have poor progression-free survival when treated with conventional chemotherapy and radiation. The BRAFV600E mutation occurs in many low-grade glial tumors that are amenable for targeted therapy using mutation-specific kinase inhibitors. However, these inhibitors’ effectiveness and best treatment duration in these tumors...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f2516462-bacd-5f83-aac3-53b14d411f3e
DOI: 10.22541/au.170670846.66848688/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Significant response to targeted therapy for Cervico-Medullary pediatric low grade glial tumors with BRAF V600E mutationDOI 10.22541/au.170670846.66848688/v1Read

Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.Semantic proximity Read

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read

[Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].Semantic proximity Read

Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudySemantic proximity Read

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read

Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.Semantic proximity Read

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.Semantic proximity Read

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Semantic proximity Read

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.Semantic proximity Read